Amvuttra

(Vutrisiran)

Amvuttra

Drug updated on 2/20/2024

Dosage FormInjection (subcutaneous; 25 mg/0.5 mL)
Drug ClassTransthyretin-directed small interfering RNA
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Amvuttra (vutrisiran) Prescribing Information. 2022Alnylam Pharmaceuticals Inc., Cambridge, MA

Randomized Controlled Trials